Neurocrine Biosciences (NBIX) M&A announcement summary

Deal rationale and strategic fit

• Acquisition expands and diversifies the rare disease and endocrinology portfolio with VYKAT XR, the only FDA-approved treatment for hyperphagia in Prader-Willi syndrome, addressing a significant unmet need.

• Adds a third first-in-class medicine, supporting sustained innovation, long-term growth, and leadership in rare diseases.

• Strong intellectual property for VYKAT XR expected to last into the mid-2040s, providing a durable platform for value creation.

• Aligns with strategy to leverage expertise in rare disease markets and neuroscience.

• Both organizations share a patient-first mindset, supporting seamless integration.

Financial terms and conditions

• All-cash transaction at $53.00 per share, valuing the deal at $2.9 billion, representing a 34% premium to the closing share price and 51% premium to the 30-day VWAP.

• Funded with cash on hand and a modest amount of pre-payable debt; not subject to financing condition.

• No shareholder dilution as no new shares will be issued.

• Expected to be immediately accretive to revenue growth in 2026 and generate strong cash flow.

Synergies and expected cost savings

• Focus is on revenue growth and portfolio diversification, with some cost synergies and operational efficiencies expected by leveraging existing infrastructure.

• Synergies anticipated in patient finding, diagnosis, education, and access initiatives.

• Commercial scale and medical capabilities in rare disease and endocrinology will be leveraged.